Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Oncologists’ views: comparisons across countries

From: Oncologists’ and family physicians’ views on value for money of cancer and congestive heart failure care

Statement % stating strongly or somewhat agree
Israel United States Canada
Only effective cancer treatments that provide “good value for money” should be included in the National List of Health Services* 44% 58% 75%
Every patient in Israel should have access to effective cancer treatments regardless of their cost 58% 67% 52%
Using data on the cost-effectiveness of cancer drugs to support decisions whether to include these drugs in the National List of Health Services should be encouraged* 76% 80% 69%
Co-payment on cancer drugs is needed even if the drugs are included in the National List of Health Services 10% 29% 41%
More research on comparative analysis of cancer drugs is needed 84% 79% 85%
Over the next five years, the high cost of new cancer drugs will cause the Public National Advisory Committee to recommend the funding of only very few new treatments* 63% 73% NA
The notion that my patients will have to pay for a cancer drug “out of pocket” will influence my decision regarding which treatment protocol to recommend to my patients 63% 84% 80%
How often do you discuss the costs of cancer drugs with your patients?    
 Always 2% 7% 7%
 Frequently 15% 36% 41%
 Occasionally 41% 37% 41%
 Rarely 32% 17% 0%
 Never 11% 3% 1%
What do you think is a reasonable definition of “good value for money” or cost-effectiveness per life-year gained ($ per life-year)    
 0–50,000 57% 21% 12%
 50,001-100,000 32% 49% 56%
 >100,000 11% 30% 33%
  1. Data for Israel is a summary of responses of all physicians (oncologists and family physicians). Data for the U.S. and Canada are summary of oncologists’ attitudes.
  2. * Statements presented to physicians in Israel were slightly different than those presented to physicians in the U.S. and Canada, and were modified to reflect the practice and health insurance structure in Israel and the access to care granted through a National List of Health Services (NLHS) in Israel.